Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9015891 | Pharmacology & Therapeutics | 2005 | 13 Pages |
Abstract
Cannabinoids, including the bioactive constituents of the marijuana plant, their synthetic analogs, and endogenous lipids with cannabinoid-like activity, produce their biological effects by interacting with specific receptors. To date, two G protein-coupled cannabinoid receptors have been identified by molecular cloning, CB1 receptors mainly expressed in the brain and mediating most of the neurobehavioral effects of cannabinoids and CB2 receptors expressed by immune and hematopoietic tissues. Recent findings indicate that some cannabinoid effects are not mediated by either CB1 or CB2 receptors, and in some cases there is compelling evidence to implicate additional receptors in these actions. These include transient receptor potential vanilloid 1 (TRPV1) receptors and as-yet-unidentified receptors implicated in the endothelium-dependent vasodilator effect of certain cannabinoids and in the presynaptic inhibition of glutamatergic neurotransmission in the hippocampus. The case for these additional receptors is being reviewed here.
Keywords
LPSAbnormal cannabidiolTransient receptor potential vanilloid receptorEDHF2-arachidonoylglycerolPTXGPCRCGRP2-AGHUVECPEATHCBKCaΔ9-TetrahydrocannabinolvasodilationEndotheliumendocannabinoidsHuman umbilical vein endothelial cellpertussis toxinEndothelium-derived hyperpolarizing factorlipopolysaccharideNitric oxideHippocampuscalcitonin gene-related peptidelarge conductance calcium-activated potassium channelcannabinoid receptorsG protein-coupled receptor
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Malcolm Begg, Pál Pacher, Sándor Bátkai, Douglas Osei-Hyiaman, László Offertáler, Fong Ming Mo, Jie Liu, George Kunos,